A multicenter prospective study to evaluate the effect of elobixibat on spontaneous defecation without a feeling of residual stool in patients with chronic constipation who are inadequately effective with magnesium oxide, a first-line treatment for constipation.

A multicenter prospective study to evaluate the effect of elobixibat on spontaneous defecation without a feeling of residual stool in patients with chronic constipation who are inadequately effective with magnesium oxide, a first-line treatment for constipation. - A multicenter prospective study to evaluate the effect of elobixibat on spontaneous defecation without a feeling of residual stool in patients with chronic constipation who are inadequately effective with magnesium oxide, a first-line treatment for constipation.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048397

Enrollment

Registered

2022-07-18

Start date

2022-07-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic constipation

Interventions

Orally administer 10 mg of elobixibat once daily before meals.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age at the time of consent acquisition is 20 years or older 2) Among those who are refractory to MgO, those with chronic constipation according to the diagnostic criteria for functional constipation of Rome IV 3) Those who start administration of elobixibat in normal medical care 4) Persons who have obtained consent from the research subject

Exclusion criteria

Exclusion criteria: 1) Patients with a history of hypersensitivity to elobixibat 2) Patients with confirmed or suspected intestinal obstruction due to tumor, hernia, etc. 3) Patients suspected of having constipation due to organic disease 4) Patients taking other laxatives 5) Others who are judged by the principal investigator to be inappropriate as research subjects

Design outcomes

Primary

Measure	Time frame
Difference in spontaneous bowel movements (SBM) before and after switching to study drug	—

Countries

Japan

Contacts

Public ContactKazuya Matsumoto

Medical corporation Irisawa Medical Clinic Internal Medicine

matsumotokazuya@tottori-u.ac.jp0852-38-8211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026